trending Market Intelligence /marketintelligence/en/news-insights/trending/yKB0fDH1dSeRrIAvQZWUbg2 content esgSubNav
In This List

Loxo Oncology director resigns

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Loxo Oncology director resigns

David Bonita resigned as a class II independent director of Loxo Oncology Inc., effective Dec. 22.

Bonita's resignation is not the result of any disagreement with the company on any matter relating to its operations, policies or practices.